CD30 - Governor of memory T cells?

Annals of the New York Academy of Sciences

Volumn 975, Issue , 2002, Pages 101-113

  Podack, Eckhard R ^a   Strbo, Natasa ^a   Sotosec, Vlatka ^a   Muta, Hiromi ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CD30; Memory T cells; T regulatory cells

Indexed keywords

CASPASE; CD16 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; FAS LIGAND; GRANULYSIN; GRANZYME A; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA CONVERTING ENZYME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METALLOPROTEINASE; PERFORIN; PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; APOPTOSIS; AUTOIMMUNE DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA MICROARRAY; EFFECTOR CELL; EXOCYTOSIS; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOMA; MEMORY CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ANIMALIA;

EID: 0036960129     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb05945.x     Document Type: Conference Paper

References (35)

1. GERDES, J., R. SCHWARTING & H. STEIN. 1986. High proliferative activity of Reed Sternberg associated antigen Ki-1 positive cells in normal lymphoid tissue. J. Clin. Pathol. 39: 993.
2. LIU, V. & P.H. MCKEE. 2002. Cutaneous T-cell lymphoproliferative disorders: approach for the surgical pathologist: recent advances and clarification of confused issues. Adv. Anat. Pathol. 9: 79.
3. HWONG, H., D. JONES, V.G. PRIETO, et al. 2001. Persistent atypical lymphocytic hyperplasia following tick bite in a child: report of a case and review of the literature. Pediatr. Dermatol. 18: 481.
4. WEITZMAN, S., K. SURYANARAYAN & H.J. WEINSTEIN. 2002. Pediatric non-Hodgkin's lymphoma: clinical and biologic prognostic factors and risk allocation. Curr. Oncol. Rep. 4: 107.
5. +): advances in biology and current therapeutic approaches. Clin. Lymphoma 2: 29.
6. KAWAMURA, T., T. INAMURA, K. IKEZAKI, et al. 2001. Primary Ki-1 lymphoma in the central nervous system. J. Clin. Neurosci. 8: 574.
7. GILFILLAN, M.C., P.J. NOEL, E.R. PODACK, et al. 1998. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J. Immunol. 160: 2180.
8. NAKAMURA, T., R.K. LEE, S.Y. NAM, et al. 1997. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J. Immunol. 158: 2648.
9. + T cells by IL-4 and IFN-gamma. J. Immunol. 158: 2090.
10. CERUTTI, A., E.C. KIM, S. SHAH, et al. 2001. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat. Immunol. 2: 150.
11. CERUTTI, A., A. SCHAFFER, R.G. GOODWlN, et al. 2000. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+ IgM+ B cells. J. Immunol. 165: 786.
12. CERUTTI, A., A. SCHAFFER, S. SHAH, et al. 1998. CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity 9: 247.
13. BOWEN, M.A., R.K. LEE, G. MIRAGLIOTTA, et al. 1996. Structure and expression of murine CD30 and its role in cytokine production. J. Immunol. 156: 442.
14. SMITH, C.A., H.J. GRUSS, T. DAVIS, et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73: 1349.
15. DUCKETT, C.S., R.W. GEDRICH, M.C. GILFILLAN & C.B. THOMPSON. 1997. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol. Cell Biol. 17: 1535.
16. DEVERGNE, O., E. HATZIVASSILIOU, K.M. IZUMI, et al. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol. Cell Biol. 16: 7098.
17. ANSIEAU, S., I. SCHEFFRAHN, G. MOSIALOS, et al. 1996. Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. Proc. Natl. Acad. Sci. USA 93: 14053.
18. ISHIDA, T., S. MIZUSHIMA, S. AZUMA, et al. 1996. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271: 28745.
19. LEE, S.Y., G. KANDALA, M.L. LIOU, et al. 1996. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc. Natl. Acad. Sci. USA 93: 9699.
20. GEDRICH, R.W., M.C. GILFILLAN, C.S. DUCKETT, et al. 1996. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J. Biol. Chem. 271: 12852.
21. LEE, S.Y., C.G. PARK & Y. CHOI. 1996. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J. Exp. Med. 183: 669.
22. HORIE, R., T. WATANABE, Y. MORISHITA, et al. 2002. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21: 2493.
23. ARCH, R.H., R.W. GEDRICH & C.B. THOMPSON. 2000. Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem. Biophys. Res. Commun. 272: 936.
24. GRUSS, H.J., N. BOIANI, D.E. WILLIAMS, et al. 1994. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 2045.
25. AMAKAWA, R., A. HAKEM, T.M. KUNDIG, et al. 1996. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84: 551.
26. DEYOUNG, A.L., O. DURAMAD & A. WINOTO. 2000. The TNF receptor family member CD30 is not essential for negative selection. J. Immunol. 165: 6170.
27. ALZONA, M., H.M. JACK, R.I. FISHER & T.M. ELLIS. 1994. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J. Immunol. 153: 2861.
28. SAEKI, H., A.M. MOORE, M.J. BROWN & S.T. HWANG. 1999. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J. Immunol. 162: 2472.
29. YOSHIDA, R., M. NAGIRA, M. KITAURA, et al. 1998. Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7. J. Biol. Chem. 273: 7118.
30. BAEKKEVOLD, E.S., T. YAMANAKA, R.T. PALFRAMAN, et al. 2001. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J. Exp. Med. 193: 1105.
31. SALLUSTO, F., D. LENIG, R. FORSTER, et al. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [see comments]. Nature 401: 708.
32. BOWEN, M.A., K.J. OLSEN, L. CHENG, et al. 1993. Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL-2R, and induction of homotypic aggregation. J. Immunol. 151: 5896.
33. MUTA, H., L.H. BOISE, L. FANG & E.R. PODACK. 2000. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis [In Process Citation]. J. Immunol. 165: 5105.
34. HOGQUIST, K.A., S.C. JAMESON, W.R. HEATH, et al. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17.
35. YAMAZAKI, K., T. NGUYEN & E.R. PODACK. 1999. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J. Immunol. 163: 5178.